Artificial Intelligence-based Early Screening of Pancreatic Cancer and High Risk Tracing (ESPRIT-AI)
NCT04743479
Chronic Disease, Chronic Pancreatitis
Shanghai, China
View Trial DetailsNCT Number: NCT06826729
The purpose of this study was to explore the characteristics of blood glucose spectrum, changes of endocrine/exocrine pancreatic function and the correlation between them in patients with PPDM-C.
Trial opening soon.
Get Notified18 year and older
All sexes
Observational
The benefits of this study to participants include:
The risks that this study may bring to participants are:
There may be some very small risks in specimen collection, including transient pain, local cyanosis, etc. a few people will have mild dizziness or extremely rare needle infection.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: From February 2025 to December 2025
Shanghai Changzheng Hospital
Other
The Characteristics of Blood Glucose Profile and the Changes of Endogenous and Exogenous Hormones in Patients with Post-chronic Pancreatitis Diabetes Mellitus
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04743479
Chronic Disease, Chronic Pancreatitis
Shanghai, China
View Trial DetailsNCT02384018
Chronic Disease, Chronic Pancreatitis
Charleston, South Carolina, United States
View Trial DetailsNCT01236053
Adenocarcinoma, Anal Cancer
View Trial DetailsNCT01138124
Adenocarcinoma, Brain Diseases
View Trial Details